Telomir Pharmaceuticals, Inc. financial data

Symbol
TELO on Nasdaq
Industry
Pharmaceutical Preparations
Location
100 Se 2 Nd St, Suite 2000 #1009, Miami, FL
State of incorporation
Florida
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Return On Equity -735 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 29.6M shares
Common Stock, Shares, Outstanding 29.6M shares
Weighted Average Number of Shares Outstanding, Basic 29.6M shares +9.27%
Weighted Average Number of Shares Outstanding, Diluted 29.6M shares +9.27%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 595K USD -10.9%
General and Administrative Expense 880K USD +1364%
Net Income (Loss) Attributable to Parent -18.7M USD +6.54%
Earnings Per Share, Basic -0.05 USD/shares +16.7%
Earnings Per Share, Diluted -0.05 USD/shares +16.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 2.1M USD
Assets 2.1M USD
Liabilities, Current 534K USD
Liabilities 534K USD
Retained Earnings (Accumulated Deficit) -21.8M USD
Stockholders' Equity Attributable to Parent 1.57M USD -59.7%
Liabilities and Equity 2.1M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.94M USD -164%
Net Cash Provided by (Used in) Financing Activities 5.21M USD +608%
Common Stock, Shares Authorized 300M shares
Common Stock, Shares, Issued 29.6M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3.27M USD +843478%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 100M shares
Additional Paid in Capital 23.3M USD
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 4.34M USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares